
NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502
An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results